DoD Peer Reviewed Alzheimer’s Transforming Diagnosis Award | HT942524PRARPTRDA

Opportunity Information: Apply for HT942524PRARPTRDA

The DoD Peer Reviewed Alzheimer's Transforming Diagnosis Award (TrDA) is a Department of Defense research grant aimed at improving Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD) diagnosis in the near term, with a strong emphasis on practical clinical usefulness rather than long-range or purely exploratory work. The core idea is to fund projects that can help people get diagnosed more effectively and earlier, track disease meaningfully over time, and improve prognostic accuracy in ways that matter to patients and families right now. The opportunity is run through the U.S. Army Medical Research Acquisition Activity (USAMRAA) under the Peer Reviewed Alzheimer's Research Program (PRARP), and it is categorized as a discretionary research and development grant in science and technology (CFDA 12.420).

Projects must directly tackle major real-world barriers that prevent accurate, timely, and accessible diagnosis and prognosis. The program explicitly recognizes that barriers can be technical (for example, limitations in diagnostic tools or biomarker performance), practical (cost, speed, workflow burdens, or challenges implementing new tools in clinics), and societal (unequal access to care, structural and social determinants of health, and lack of applicability across different communities). It also calls out gaps like insufficient longitudinal data needed to make reliable predictions about disease trajectory and challenges in validating biomarkers against clinical outcomes. A key expectation is that the applicant clearly identifies the specific barrier being targeted and explains how the proposed work will reduce or overcome it, rather than simply adding incremental knowledge without changing what is feasible in real clinical settings.

A defining feature of the TrDA mechanism is that it demands a clear pathway to clinical applicability. The proposed research should not stop at demonstrating something in an idealized setting; it should show how the work moves toward equitable, accessible, and rapid diagnostic and/or prognostic use. Applications that do not convincingly map their aims to overcoming an access or implementation barrier are considered misaligned with the award's intent. Another major requirement is that the work represent a non-incremental advance over the current state of the field. This is not meant for small next-step studies; the program expects an appreciable leap forward, and preliminary data are required to support feasibility and justify the claim of meaningful advancement.

The opportunity is also explicitly person-focused. The program stresses that even the most technically strong diagnostic or prognostic approach will fail to make an impact if the people living with AD/ADRD, their families, and care partners do not trust it, understand it, or see its relevance. As a result, applicants must design projects around the needs of those most affected and partner with them in a real and sustained way. For the FY24 TrDA, community collaboration is required for all projects, and this is treated as a central scientific and translational component of the work rather than an optional outreach activity.

Equity, representativeness, and cultural competence are not side notes in this funding call; they are core review expectations. Every application must explain how the research will be representative of the population it aims to benefit, and it must demonstrate cultural competence in how the research questions are framed, how participants are engaged, how procedures are carried out, and how results will be implemented. The notice makes a direct connection between cultural competence and reducing health disparities, emphasizing that research quality and real-world impact depend on being inclusive, responsive, and grounded in the lived realities of diverse groups. It also highlights the importance of ensuring that advances are applicable to diverse populations and specifically flags the inclusion of women as a priority consideration in designing equitable and representative study populations.

To operationalize community collaboration, the award requires that investigators host a community meeting with a facilitated discussion within the first three quarters of the project period. This meeting must involve the intended research population and their community, and it is intended to generate feedback that actively shapes how the research is executed. The program expects this input to help refine research questions, improve implementation choices, and inform dissemination strategies so that findings do not just remain in academic channels but get communicated and translated in ways that are useful to affected communities.

The funding announcement describes several acceptable models for community collaboration, all of which center on shared responsibility and meaningful involvement rather than symbolic participation. Examples include integrating lived experience consultants (such as a person with AD/ADRD, a family member, or a caregiver) as ongoing advisors; partnering with community-based organizations like advocacy groups or service providers; or forming a community advisory board (CAB) composed of multiple stakeholders. The emphasis is on equitable partnerships where community members contribute across phases of the project, which may include needs assessment, planning, study design, implementation, evaluation, and dissemination. The program frames approaches like community-based participatory research and participatory action research as strong fits because they support co-interpretation of results, feedback loops to communities, and translation into practice or policy where appropriate.

From an administrative standpoint, the opportunity number is HT942524PRARPTRDA, the original closing date listed is June 20, 2024, and the agency lists expected awards as two. Eligibility is described as unrestricted, meaning the opportunity is broadly open to applicant types that meet standard federal grant requirements. Overall, the TrDA is designed for teams that can bring credible preliminary evidence, a strong translational plan, and authentic community partnership together into a project that measurably improves how AD/ADRD is diagnosed, monitored, and prognosed in ways that are accessible, equitable, and ready to move toward clinical use.

• The Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Peer Reviewed Alzheimer’s Transforming Diagnosis Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on 2024-03-25.
• Applicants must submit their applications by 2024-06-20. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 2 candidate(s).
• Eligible applicants include: Unrestricted.

Apply for HT942524PRARPTRDA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: